MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

AnaptysBio Inc

Closed

SectorHealthcare

20.58 0.44

Overview

Share price change

24h

Current

Min

20.47

Max

20.76

Key metrics

By Trading Economics

Income

11M

-22M

Sales

13M

43M

EPS

-0.72

Profit margin

-50.528

Employees

136

EBITDA

13M

-3.8M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+107.73% upside

Dividends

By Dow Jones

Next Earnings

7 maj 2025

Market Stats

By TradingEconomics

Market Cap

183M

632M

Previous open

20.14

Previous close

20.58

Technical Score

By Trading Central

Confidence

Bullish Evidence

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 kwi 2025, 17:01 UTC

Earnings
Major Market Movers

Aon Shares Sink After 1Q Profit Falls, Sales Miss Estimates

25 kwi 2025, 16:10 UTC

Earnings
Major Market Movers

Coursera Shares Rise After 1Q Beat, Better-Than-Expected Revenue View

26 kwi 2025, 18:14 UTC

Earnings

Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings -- Barrons.com

26 kwi 2025, 15:00 UTC

Earnings
Acquisitions, Mergers, Takeovers

Trump 2.0 Era Brings Flurry of Crypto Deals -- WSJ

26 kwi 2025, 08:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

25 kwi 2025, 21:24 UTC

Top News

Cargo Shipments From China to the U.S. Dwindle -- WSJ

25 kwi 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

25 kwi 2025, 20:45 UTC

Top News

Stocks Claw Back Most of April's Tariff Losses -- WSJ

25 kwi 2025, 20:39 UTC

Earnings

The Score: Tesla, Capital One, Boeing and More Stocks That Defined the Week -- WSJ

25 kwi 2025, 20:37 UTC

Top News

Trump Administration Lays Out Tariff Roadmap to Streamline Trade Talks -- WSJ

25 kwi 2025, 20:19 UTC

Top News

Nasdaq Climbs More Than 1% as Stocks Finish Strong Week -- WSJ

25 kwi 2025, 20:15 UTC

Earnings

Week's Best: A Dividend Expert's Best Advice -- Barrons.com

25 kwi 2025, 19:23 UTC

Market Talk

U.S. Natural Gas Futures Extend Weekly Losses -- Market Talk

25 kwi 2025, 19:18 UTC

Market Talk

Oil Futures End Choppy Week With Losses -- Market Talk

25 kwi 2025, 18:47 UTC

Market Talk

Gold Extends Pullback to Close Week -- Market Talk

25 kwi 2025, 18:39 UTC

Top News

Nasdaq, Dow Industrials About Flat; Analysts Caution on Trump Tariffs -- WSJ

25 kwi 2025, 18:34 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs Upgrades Schwab Stock. Here's Why. -- Barrons.com

25 kwi 2025, 18:32 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

25 kwi 2025, 18:32 UTC

Market Talk
Earnings

Carriers See Tariffs Driving Up Phone Prices, Slowing Upgrades -- Market Talk

25 kwi 2025, 18:08 UTC

Earnings

Sphere Entertainment Deal Is a Win for Shareholders as Banks Take a Hit -- Barrons.com

25 kwi 2025, 17:55 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 483 -- Market Talk

25 kwi 2025, 17:40 UTC

Top News

Consumers Continue to Sour on the Economy -- 4th Update

25 kwi 2025, 17:38 UTC

Earnings

Centene Stock Falls on Medicaid Cost Worries -- Barrons.com

25 kwi 2025, 17:07 UTC

Market Talk

Oil Futures Turn Higher in Quiet Trade -- Market Talk

25 kwi 2025, 16:54 UTC

Market Talk
Earnings

Mobile Carriers See Stronger Activity on Bigger Price Tags, Tariffs -- Market Talk

25 kwi 2025, 16:46 UTC

Earnings

Reddit, Meta, and Pinterest Stocks Rise. How Alphabet's Earnings Are Giving Them a Boost. -- Barrons.com

25 kwi 2025, 16:20 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

25 kwi 2025, 16:12 UTC

Top News

Dow Industrials Fall; China Plans Economic Support During Trade Battle -- WSJ

25 kwi 2025, 16:03 UTC

Earnings

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 kwi 2025, 15:52 UTC

Market Talk

Grains Mixed on Low Volume Trade -- Market Talk

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

107.73% upside

12 Months Forecast

Average 43 USD  107.73%

High 57 USD

Low 22 USD

Based on 11 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

9

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

20.4 / 22.29Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.